SCHEMBL6860202

SCHEMBL6860202

CCCC[C@H](CC(=O)O)C(=O)OC1c2ccccc2-c2ccccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.43
TSHR P16473 1/20 0.43
MMP2 P08253 10/20 0.42
MMP9 P14780 1/20 0.42
MMP12 P39900 1/20 0.42
MMP1 P03956 4/20 0.39
MMP3 P08254 4/20 0.39
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
PRSS1 P07477 1/20 0.38
CTSG P08311 1/20 0.38
CTRB1 P17538 1/20 0.38
CMA1 P23946 1/20 0.38
CNR2 P34972 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28656072 0.79 BCHE (0.42) TSHRBCHEACHEPRSS1CNR2
SCHEMBL4265489 0.73 CYP2D6 (0.41) CYP1A2TSHRALDH1A1MAPK1KMT2A
SCHEMBL2740693 0.72 POLB (0.45) CYP1A2TSHRBCHEACHEMEN1
SCHEMBL29063086 0.71 CA2 (0.46) TSHRMEN1ALDH1A1MAPTMAPK1
SCHEMBL685354 0.71 POLB (0.50) CYP1A2TSHRMEN1KMT2APOLB
SCHEMBL27878603 0.71 BCHE (0.49) BCHEACHEMEN1KMT2APOLB
SCHEMBL8209048 0.70 MMP2 (0.53) TSHRMMP2MMP9MMP12MMP1
SCHEMBL29271867 0.70 MMP2 (0.54) MMP2MMP9MMP12MMP1MMP3
SCHEMBL8209047 0.70 MMP2 (0.53) TSHRMMP2MMP9MMP12MMP1
SCHEMBL27563105 0.70 POLB (0.42) CYP1A2TSHRBCHEACHEKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6797820-B2 HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS VICURON PHARMACEUTICALS INC. 2004-09-28 US disclosed
US-20020115863-A1 Novel succinate compounds, compositions and methods of use and preparation VICURON HOLDINGS LLC 2002-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115863-A1 Novel succinate compounds, compositions and methods of use and preparation PDF, MMP2, SDHA CYP1A2 1521/4885TSHR 4589/4885MMP2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.